Key result
iPSC-derived cardiomyocyte models increasingly advance disease modeling and drug discovery in inherited cardiac arrhythmias.
Why the study?
Traditional 2D iPSC-CM models are immature compared with adult cardiomyocytes, prompting novel 3D models to improve physiological relevance for inherited cardiac arrhythmia modelling and drug development.
This review summarizes the advancements in using 2D and 3D iPSC-derived cardiomyocyte models for studying inherited cardiac arrhythmias and developing new therapies.
Answers are grounded in this paper and cite their sources.
iPSC models should not yet alter arrhythmia management; extends preclinical research toolkit for inherited conditions.
With the discovery of induced pluripotent stem cell (iPSCs) a wide range of cell types, including iPSC-derived cardiomyocytes (iPSC-CM), can now be generated from an unlimited source of somatic cells. These iPSC-CM are used for different purposes such as disease modelling, drug discovery, cardiotoxicity testing and personalised medicine. The 2D iPSC-CM models have shown promising results, but they are known to be more immature compared to in vivo adult cardiomyocytes. Novel approaches to create 3D models with the possible addition of other (cardiac) cell types are being developed. This will not only improve the maturity of the cells, but also leads to more physiologically relevant models that more closely resemble the human heart. In this review, we focus on the progress in the modelling of inherited cardiac arrhythmias in both 2D and 3D and on the use of these models in therapy development and drug testing.
No takes yet. Share an insight, caveat, or question.
Simons et al. (2023) conducted a review in Inherited cardiac arrhythmias. iPSC-derived cardiomyocytes was evaluated. iPSC-derived cardiomyocyte models, both 2D and 3D, are increasingly used for disease modeling, drug discovery, and personalized medicine in inherited cardiac arrhythmias.
Synapse has enriched 10 related papers. Consider them for comparative context: